Blood-Based Biomarkers for Post-Stroke Cognitive Impairment

Le résumé fourni par la source

Stroke remains the second leading cause of death and the third leading cause of death and disability. With the growing incidence of strokes, the incidence of post-stroke cognitive impairment (PSCI) among patients is on a steady rise. These patients commonly present with impairments in memory, attention, executive function, comprehension, and judgment, substantially affecting their everyday lives. Magnetic resonance image (MRI) and cognitive assessment scales are widely employed as diagnostic tools for PSCI. They also have notable limitations. Furthermore, cerebrospinal fluid collection is relatively complex. Growing evidence suggests that blood-based biomarkers are closely involved in the onset and progression of PSCI, as bioassay techniques and equipment have become increasingly popular and optimized. Therefore, blood-based biomarkers play an essential role in the pathogenesis and progression of PSCI. This review concentrates on the research progress of blood-based biomarkers in PSCI to explore their significance for disease identification, with the aim of offering novel insights into the clinical diagnosis and therapy of PSCI.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.